CPS

Webinar Archive

Precision Pathology Insights webinar series gives you access to leading perspectives on PD-L1 with expert speakers at the top of their field. Browse the full catalog of previous live events here.

 

Expert Walkthroughs of HNSCC Specimens Using the Next-Generation Atlas of Stains

Date: 30 Nov 2023
Presenter: Dr. Quyen Nguyen, MD, CPA (Pathologist, Agilent Technologies)
View Recording

Expert Walkthroughs of Esophageal Cancer Specimens Using the Next-Generation Atlas of Stains

Date: 28 Sep 2023
Presenter: Dr. Emmanuel Agosto-Arroyo, MD (Pathologist, Agilent Technologies)
View Recording

Evaluating PD-L1 Across a Range of Tumor Types using Combined Positive Score (CPS)

Date: 21 Jun 2023
Presenter: Ed Manna, CDx Pathology Manager, Agilent Technologies
View Recording

Double Feature: PD-L1 Interpretation in Esophageal and Cervical Cancer

Date: 16 Nov 2022
Presenter: Prof. Dr. Dr. Jens Neumann, Managing Senior Physician, Institute of Pathology, Medical Faculty, LMU Munich and Kristopher Kersch, MD, Pathologist, Agilent Technologies
View Recording

Confidence in Evaluating Combined Positive Score: How a Systematic Approach Can Simplify PD-L1 Scoring with CPS

Date: 16 Jun 2022
Presenter: Hans-Ulrich Schildhaus, Professor Dr. med., University Hospital Essen & West German Cancer Center Essen, Germany
View Recording

Scoring of Triple-Negative Breast Cancer (TNBC): Example Cases from PD-L1 IHC 22C3 pharmDx Atlas of Stain

Date: 11 Nov 2021
Presenter: Dr. Allen M. Gown, founder of PhenoPath Laboratories and Clinical Professor of Pathology at the University of British Columbia, Vancouver
View Recording

Assessing PD-L1 Combined Positive Score (CPS) in Various Tumor Types with Distinct Morphological Characteristics

Date: 07 Oct 2021
Presenter: Dr. Philippe Tanière, histopathologist at University Hospitals Birmingham
View Recording

PD-L1 IHC 22C3 pharmDx and NSCLC One Assay, Two Platforms

Date: 08 Dec 2020
Presenter: Grant Toland, R&D Scientist, Agilent Technologies
View Recording

The Nuances of Tumor Types: How are Cutoffs Determined and Validated?

Date: 05 Nov 2020
Presenter: Dr. Kristopher Kersch, MD, Pathologist, Agilent Technologies and Karina Kulangara, PhD, R&D Director, Agilent Technologies
View Recording

Implementation of PD-L1 Testing in the New Era of an Everchanging Immuno-oncology Landscape

Date: 24 Sep 2020
Presenter: Dr. Carol Cheung, MD, PhD, JD, FRCPC, University Health Network, University of Toronto, Canada
View Recording

Mastering Combined Positive Score (CPS) From Principles to Real-world Applications

Date: 27 May 2020
Presenter: Dr. Quyen Nguyen, MD, CPA, Pathologist, Agilent Technologies
View Recording

The Pathologist and the Oncologist Working Together on PD-L1 to Improve Patient Treatment

Date: 11 Dec 2019
Presenter: Dr. Jose Ramirez, MD, Professor of Pathology, University of Barcelona, Spain and Dr. Noemí Reguart Aransay, MD, PhD, Consultant Oncologist, Hospital Clinic of Barcelona, Spain
View Recording

External Quality Assurance of PD-L1 Assays The NordiQC Experience

Date: 04 Dec 2019
Presenter: Dr. Mogens Vyberg, MD, Consultant, NordiQC, Professor, Aalborg University, Denmark
View Recording

The Rationale Behind the Scoring Systems for PD-L1 IHC to Determine Patients Eligible for KEYTRUDA (pembrolizumab)

Date: 24 Sep 2019
Presenter: Dr. Kristopher Kersch, MD Pathologist, Agilent Technologies; United States
View Recording

The Value of CDx IHC Assays in the Complex Environment of PD‑L1 Testing

Date: 28 May 2019
Presenter: Dr. Allen Gown, MD, Clinical Professor of Pathology, University of British Columbia, Vancouver, Canada
View Recording

This website addresses general principles for scoring of PD-L1 IHC 22C3 pharmDx and is for education purposes only. Not all cancer indications mentioned are approved worldwide. Please refer to local Instructions for Use for PD-L1 IHC 22C3 pharmDx for further details.

 

D72742_2.00